Abstract 152P
Background
The detection of copy number alterations (CNAs) is an informative molecular layer in the diagnosis, prognosis, and treatment of lung adenocarcinoma. Traditional tissue biopsies are invasive and often impractical. This study investigates the use of nanopore sequencing on circulating cell-free DNA (cfDNA) as a non-invasive, PCR-free method to detect CNAs in lung adenocarcinoma patients.
Methods
Native cfDNA samples from lung adenocarcinoma patients were analysed using low coverage nanopore sequencing (∼ 1- 3 X). Bioinformatics analysis identified CNAs, which were compared to known CNA patterns in tissue samples. Additionally, tumor fractions were estimated to correlate with tumor stage and aggressiveness.
Results
Nanopore sequencing of cfDNA revealed clinically significant and informative CNAs, including amplifications of 1q (MDM4), chromosome 7 (EGFR) as well as deletion of 8p. These alterations closely mirrored the classic CNA patterns observed in lung adenocarcinoma tissue samples, especially in cfDNA samples derived from patients with progressive cancers (i.e. stage 3-4). The analysis also provided tumor fraction estimates, which correlated with tumor stage and aggressiveness.
Conclusions
This study demonstrates that nanopore sequencing of cfDNA can accurately detect CNAs and estimate tumor fractions, offering a non-invasive alternative to tissue biopsies. This approach holds significant potential for real-time cancer monitoring, prognosis prediction, targeted therapy, and precise cancer subtyping. Estimating tumor fractions is also useful for predicting cancer progression and determining future sequencing coverage and planning.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Renovaro Cube.
Disclosure
K. Roohollahi, E. Post, D. Makarawung, F. van Asch: Financial Interests, Institutional, Stocks/Shares: Renovaro Cube. D. Vessies, J. van den Berg: Financial Interests, Personal, Stocks/Shares: Renovaro Cube.
Resources from the same session
35P - Whole exome sequencing reveals high frequency of Notch pathway mutations in Indian breast cancer cases
Presenter: Harsh Goel
Session: Cocktail & Poster Display session
Resources:
Abstract
36P - Abacavir potentiates the efficacy of doxorubicin in breast cancer cells via KDM5B Inhibition
Presenter: Anmi Jose
Session: Cocktail & Poster Display session
Resources:
Abstract
37P - Identification of immune profile in advanced cutaneous squamous cell carcinoma predicting immunotherapy response
Presenter: Alfonso Esposito
Session: Cocktail & Poster Display session
Resources:
Abstract
39P - MicroRNA as a promising molecular biomarker for liquid biopsy in breast cancer
Presenter: Giorgia Vesca
Session: Cocktail & Poster Display session
Resources:
Abstract
40P - Patient-based models to study infiltration heterogeneity in gliomas
Presenter: Ivana Manini
Session: Cocktail & Poster Display session
Resources:
Abstract
42P - HER2 aberration as a potential predictive biomarker for extrapulmonary small cell neuroendocrine carcinoma
Presenter: Jiri Dvorak
Session: Cocktail & Poster Display session
Resources:
Abstract
43P - Assessment of methylation-specific genetic markers for reliable colorectal cancer detection and their potential in liquid biopsy applications
Presenter: Jiri Dvorak
Session: Cocktail & Poster Display session
Resources:
Abstract
44P - Calculated numerical karyotype with ultra low-coverage whole genome sequencing undercovers recurrent chromosomal aberrations in resectable colorectal cancer
Presenter: Thomas Samer Tarawneh
Session: Cocktail & Poster Display session
Resources:
Abstract
46P - Promising epi(genetic) biomarkers for ovarian tumor prognosis
Presenter: Ieva Vaicekauskaitė
Session: Cocktail & Poster Display session
Resources:
Abstract
47P - Integration of miRNA profiles and p53 mutations as biomarkers for predicting sensitivity and resistance to FGFR inhibitor CPL110 in cancer therapy
Presenter: Monika Skupinska
Session: Cocktail & Poster Display session
Resources:
Abstract